Does Anthem (Elevance Health) Cover Low-Dose Naltrexone?
Anthem (Elevance Health) coverage policy for low-dose naltrexone (LDN): prior authorization criteria, formulary tier, step therapy requirements, appeal process, and cost-saving alternatives.
Low Dose Naltrexone
76 source-based articles maintained by the HealthRX.com Editorial Team.
76articles
4topic areas covered
May 25, 2026latest review
Low Dose Naltrexone library
Showing 60 of 76 clinical reviews.
Does Cigna Cover Low-Dose Naltrexone?
A clinical guide to Cigna coverage, prior authorization, step therapy, formulary tier, appeals, and cash-pay options for low-dose naltrexone (LDN) in 2025.
Does Humana Cover Low-Dose Naltrexone?
A guide to Humana's coverage policies, prior authorization requirements, formulary status, and appeal pathways for low-dose naltrexone (LDN) in 2024.
Does Kaiser Permanente Cover Low-Dose Naltrexone?
A detailed guide to Kaiser Permanente's coverage policy, formulary status, prior-authorization requirements, step-therapy rules, and appeal process for low-dose naltrexone (LDN), with cash-pay alternatives and clinical evidence.
Does State Medicaid Cover Low-Dose Naltrexone? A State-by-State Guide
Learn whether your state Medicaid program covers low-dose naltrexone (LDN), how to manage prior authorization, formulary tiers, step therapy rules, and the fair-hearing appeal process.
Does TRICARE Cover Low-Dose Naltrexone?
A guide covering TRICARE formulary status, prior-authorization criteria, step-therapy requirements, appeal pathways, and out-of-pocket costs for low-dose naltrexone (LDN).
Does UnitedHealthcare Cover Low-Dose Naltrexone?
A clinical and insurance guide to UnitedHealthcare coverage for low-dose naltrexone (LDN), including formulary tier, prior authorization criteria, step therapy requirements, appeals, and cash-pay alternatives.
How to Get Low-Dose Naltrexone in Arizona
A guide to obtaining a low-dose naltrexone (LDN) prescription in Arizona, covering telehealth options, compounding pharmacies, required labs, and dosing, with primary-source citations throughout.
How to Get Low-Dose Naltrexone in Delaware
A guide to obtaining a low-dose naltrexone (LDN) prescription in Delaware, covering telehealth access, compounding pharmacies, lab requirements, and Delaware Medicaid prior authorization.
How to Get Low-Dose Naltrexone in District of Columbia
A step-by-step guide to getting a low-dose naltrexone (LDN) prescription in Washington, DC, including telehealth options, compounding pharmacies, labs, insurance, and DC Medicaid prior authorization.
How to Get Low-Dose Naltrexone in Kentucky
A complete guide to obtaining a low-dose naltrexone (LDN) prescription in Kentucky, including telehealth options, compounding pharmacies, costs, and prescriber requirements.
How to Get Low-Dose Naltrexone in Montana
A step-by-step guide to obtaining a low-dose naltrexone (LDN) prescription in Montana, including telehealth options, compounding pharmacies, labs, and cost.
How to Get Low-Dose Naltrexone in Nebraska
A step-by-step guide to obtaining a low-dose naltrexone (LDN) prescription in Nebraska, including telehealth options, compounding pharmacies, costs, and what labs your provider may order first.
How to Get Low-Dose Naltrexone in Virginia
A guide to obtaining a low-dose naltrexone (LDN) prescription in Virginia, covering telehealth options, compounding pharmacy requirements, labs, dosing, and insurance coverage.
Low-Dose Naltrexone (LDN) Dosing for Adults 30, 49: Start Low, Titrate Slow
Evidence-based guide to low-dose naltrexone dosing in adults aged 30, 49, covering initiation, titration, timing, and clinical considerations for off-label use in fibromyalgia, autoimmune conditions, and chronic inflammation.
Low-Dose Naltrexone (LDN) Dosing for Young Adults (18 to 29)
Evidence-based guide to low-dose naltrexone dosing in young adults aged 18 to 29, covering titration schedules, fertility considerations, and clinical monitoring.
Low-Dose Naltrexone Access: A Seven-State Verification Guide
How to verify low-dose naltrexone access in Arizona, Delaware, DC, Kentucky, Montana, Nebraska, and Virginia without relying on stale price, coverage, telehealth, or compounding claims.
Low-Dose Naltrexone Adolescent (12 to 17) Dosing: A Clinical Guide
Evidence-based dosing guidance for low-dose naltrexone (LDN) in adolescents aged 12 to 17, including starting doses, titration schedules, monitoring requirements, and safety considerations for off-label use in inflammation, fibromyalgia, and autoimmune conditions.
Low-Dose Naltrexone After Bariatric Surgery: What You Need to Know
A clinician-level guide to using compounded low-dose naltrexone (LDN) after bariatric surgery, covering altered pharmacokinetics, dosing strategies, safety data, and current clinical evidence.
Low-Dose Naltrexone and Cognitive Function: What the Evidence Actually Shows
An evidence-based breakdown of how low-dose naltrexone (LDN) affects cognitive function, brain fog, neuroinflammation, and mental clarity, including trial data, mechanisms, dosing, and clinical context.
Low-Dose Naltrexone and Liver Function: What the Evidence Actually Shows
A guide to how low-dose naltrexone (LDN) affects liver enzymes and hepatic safety, covering clinical trial data, FDA labeling, monitoring protocols, and who should avoid LDN entirely.
Low-Dose Naltrexone and Sleep Architecture: What the Evidence Actually Shows
Does low-dose naltrexone change REM or deep sleep? A source-grounded review of the human evidence, vivid dreams, insomnia, timing, opioid interactions, and evidence gaps.
Low-Dose Naltrexone Bone Health and Density Impact
An evidence-based look at how low-dose naltrexone (LDN) affects bone density, osteoclast activity, and fracture risk, with primary-literature citations throughout.
Low-Dose Naltrexone Cancer Risk Signal Review
A clinician-level review of the evidence on low-dose naltrexone (LDN) and cancer risk, covering proposed mechanisms, human trial data, preclinical findings, and practical prescribing considerations.
Low-Dose Naltrexone Cardiovascular Impact: Long-Term Evidence and Clinical Guidance
A comprehensive analysis of low-dose naltrexone (LDN) and its long-term cardiovascular effects, covering mechanistic data, clinical trials, safety signals, and prescribing guidance for telehealth clinicians.
Low-Dose Naltrexone Cost vs. Alternatives: A Clinical and Financial Comparison
Low-dose naltrexone (LDN) costs $30-$60/month from compounding pharmacies. Compare LDN pricing, mechanism, and evidence against pregabalin, hydroxychloroquine, and biologics for fibromyalgia and autoimmune conditions.
Low-Dose Naltrexone Dosing for Older Adults (50-64): Evidence-Based Guide
How to dose low-dose naltrexone (LDN) for adults aged 50-64, including titration schedules, polypharmacy considerations, and age-specific clinical evidence.
Low-Dose Naltrexone Dosing in Hepatic Impairment: A Clinical Guide
Evidence-based dosing guidance for low-dose naltrexone (LDN) in patients with hepatic impairment, including mechanism of action, pharmacokinetics, monitoring parameters, and compounding considerations reviewed by HealthRX.com physicians.
Low-Dose Naltrexone Dosing in Renal Impairment
Evidence-based guide to low-dose naltrexone (LDN) dosing adjustments in patients with kidney disease, covering pharmacokinetics, safety data, and clinical monitoring protocols.
Low-Dose Naltrexone During Pregnancy and Lactation: What the Evidence Says
A guide to low-dose naltrexone (LDN) safety during pregnancy and breastfeeding, covering animal data, human case reports, FDA labeling, mechanism of action, and clinical decision-making.
Low-Dose Naltrexone Food & Supplement Interactions
A clinical guide to food and supplement interactions with low-dose naltrexone (LDN), including timing, absorption effects, and what to avoid for optimal efficacy.
Low-Dose Naltrexone for Autoimmune Disease: What the Evidence Actually Shows
A guide to low-dose naltrexone (LDN) for autoimmune conditions, covering mechanisms, clinical trial data, dosing, safety, and who may benefit.
Low-Dose Naltrexone Geriatric (65+) Dosing: What Older Adults and Their Clinicians Need to Know
A guide to compounded low-dose naltrexone dosing in adults aged 65 and older, covering starting doses, renal adjustment, fall risk, drug interactions, and deprescribing considerations.
Low-Dose Naltrexone Geriatric (65+) Safety: What Older Adults Need to Know
A guide to low-dose naltrexone (LDN) safety in adults 65 and older, covering renal dosing, drug interactions, fall risk, and deprescribing considerations.
Low-Dose Naltrexone Hair and Skin Changes: What the Evidence Actually Shows
A guide to how low-dose naltrexone (LDN) affects hair growth, hair loss, skin inflammation, and dermatologic autoimmune conditions, with primary-literature citations and dosing context.
Low-Dose Naltrexone in Special Populations: Transplant, HIV, Cancer, Pregnancy, and Pediatric Considerations
Evidence-based guide to using low-dose naltrexone (LDN) in special populations including transplant recipients, people living with HIV, cancer patients, pregnant individuals, children, and those with hepatic or renal impairment.
Low-Dose Naltrexone Manufacturing, Supply & Shortage History
A clinical guide to how low-dose naltrexone (LDN) is manufactured, its compounding pharmacy supply chain, FDA shortage records, and what patients should know about sourcing reliable LDN.
Low-Dose Naltrexone Mechanism of Action: Full Pathway Explained
How low-dose naltrexone (LDN) works at the molecular level. Opioid receptor blockade, glial modulation, endorphin rebound, and immune regulation explained with PubMed-cited evidence.
Low-Dose Naltrexone Mental Health and Mood Impact
How low-dose naltrexone (LDN), typically 1.5 to 4.5 mg, may affect depression, anxiety, and mood, with an honest read of the trial evidence, mechanisms, dosing considerations, and safety limits.
Low-Dose Naltrexone Missed-Dose Protocol: What to Do and Why It Matters
Evidence-based guidance on what to do when you miss a dose of low-dose naltrexone (LDN), plus a full mechanistic explainer, dosing schedules, and FAQ.
Low-Dose Naltrexone Monitoring for Adults (30 to 49): Lab Schedule, Side Effects, and Follow-Up
A clinical guide to monitoring low-dose naltrexone (LDN) in adults aged 30 to 49, covering baseline labs, liver function tests, follow-up schedules, and dose-titration checkpoints.
Low-Dose Naltrexone Monitoring for Older Adults (50 to 64): A Complete Clinical Guide
A guide to monitoring low-dose naltrexone (LDN) in adults aged 50 to 64, covering lab schedules, drug interactions, polypharmacy risks, and dose titration protocols.
Low-Dose Naltrexone Monitoring in Adolescents Ages 12 to 17
A guide to monitoring compounded low-dose naltrexone (LDN) in adolescents ages 12 to 17, covering dosing, lab schedules, growth tracking, mental-health screening, and safety signals.
Low-Dose Naltrexone Monitoring Schedule: Labs & Exams Your Prescriber Should Order
A complete monitoring schedule for low-dose naltrexone (LDN), including baseline labs, liver function tests, inflammatory markers, thyroid panels, and follow-up exam timing backed by clinical evidence.
Low-Dose Naltrexone Muscle Preservation Strategies: A Clinical Deep-Dive
How low-dose naltrexone (LDN) may support muscle preservation through glial modulation, cytokine reduction, and IGF-1 pathway effects. MD/PharmD-level review with primary literature, dosing guidance, and a decision framework.
Low-Dose Naltrexone Off-Label Uses: Evidence Levels for Every Indication
A breakdown of every major off-label use of low-dose naltrexone (LDN), graded by evidence level, with doses, trial data, and clinical context.
Low-Dose Naltrexone Overdose & Accidental Excess Dose: What to Do and What to Expect
Clinical guide to managing low-dose naltrexone (LDN) overdose and accidental excess doses, including symptoms, timelines, opioid receptor blockade duration, and when to seek emergency care.
Low-Dose Naltrexone Patent Status and Generic Timeline
A clinical review of naltrexone's patent history, current compounding status, FDA-approved formulations, and the regulatory path for a dedicated low-dose naltrexone product.
Low-Dose Naltrexone Pediatric (Under 12) Dosing: What Clinicians and Parents Need to Know
A guide to compounded low-dose naltrexone dosing in children under 12, covering weight-based calculations, safety monitoring, off-label evidence, and FDA regulatory context.
Low-Dose Naltrexone Pediatric (Under 12) Monitoring: A Clinical Guide
Complete monitoring guide for low-dose naltrexone (LDN) in children under 12, covering weight-based dosing, lab schedules, safety signals, and what parents and clinicians need to track at every visit.
Low-Dose Naltrexone Pediatric Safety: What Parents and Clinicians Need to Know About LDN in Children Under 12
Is low-dose naltrexone safe for children under 12? Review the evidence on LDN pediatric dosing, safety signals, off-label use, and monitoring requirements for young patients.
Low-Dose Naltrexone Pharmacogenomics: How Genetic Variability Shapes LDN Response
Why some patients respond to low-dose naltrexone and others don't. OPRM1, CYP2D6, and other gene variants that influence LDN metabolism, receptor binding, and clinical outcomes.
Low-Dose Naltrexone Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion
A clinical review of low-dose naltrexone (LDN) pharmacokinetics covering ADME, the role of 6-beta-naltrexol, transient opioid receptor blockade, and how compounded 1 to 4.5 mg dosing differs from standard 50 mg naltrexone.
Low-Dose Naltrexone Pre-Surgery Hold Window: What Clinicians and Patients Need to Know
How long before surgery should you stop low-dose naltrexone? This MD/PharmD-level guide covers the evidence-based hold window, opioid-antagonism pharmacokinetics, anesthesia risks, and restart timing after your procedure.
Low-Dose Naltrexone Real-World Evidence: What Registries and Observational Data Actually Show
A clinical review of real-world evidence for low-dose naltrexone (LDN), including national prescription registries, observational cohorts, and patient-reported outcomes across fibromyalgia, autoimmune, and inflammatory conditions.
Low-Dose Naltrexone Rebound Effects When Stopping: What the Evidence Says
Does stopping low-dose naltrexone cause rebound pain, inflammation, or withdrawal? A deep dive into the pharmacology, trial data, and tapering protocols for LDN discontinuation.
Low-Dose Naltrexone Regulatory Status: US, EU, Canada, and UK
A clinician-level breakdown of how low-dose naltrexone (LDN) is regulated in the United States, European Union, Canada, and United Kingdom, covering compounding rules, prescribing authority, and what that means for patients in 2025.
Low-Dose Naltrexone Safety for Adults (30 to 49): Side Effects, Risks, and What the Evidence Shows
A clinical review of low-dose naltrexone (LDN) safety in adults aged 30 to 49, covering side effects, drug interactions, liver concerns, and trial data.
Low-Dose Naltrexone Safety for Young Adults (Ages 18 to 29): What the Evidence Actually Shows
A guide to low-dose naltrexone (LDN) safety in adults aged 18 to 29, covering dosing, side effects, fertility, drug interactions, and the current trial evidence.
Low-Dose Naltrexone Safety in Adolescents (Ages 12 to 17)
A guide to low-dose naltrexone (LDN) safety in adolescents aged 12 to 17, covering evidence, dosing, monitoring protocols, and when to avoid use.
Showing the first 60 matches among the loaded articles. Use the page links below to browse the complete library.
